Understanding the ability of different chemotherapeutics to drive the nuclear translocation of MCL1 could be key to developing combination strategies with Bcl-xL inhibitors, overcoming chemoresistance, and improving CRC patient outcome. Here, BCL2L1 is linked to colorectal carcinoma.